Contribution of 68Ga-DOTA-FAPI-04 PET/CT to Prostate Cancer Imaging
Authors:
- 25 January 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 49 (3) , e105-e110
Abstract
Purpose: Prostate-specific membrane antigen (PSMA)–targeted PET/CT is a well-established imaging method in prostate cancer (PC) for both staging and restaging, and also for theranostic applications. An alternative imaging method is crucial for 15% PSMA-negative cases. We aimed to investigate the contribution of 68Ga-DOTA-FAPI-04 PET/CT to PC imaging. Patients and Methods: Thirty-six patients diagnosed with PC were included. Patients underwent both 68Ga-PSMA PET/CT and 68Ga-DOTA-FAPI-04 PET/CT imaging within 1 week. In staging group, primary tumor uptake values were compared, and also correlations were done with histopathological findings, MRI findings, and total PSA levels. In biochemical recurrence group, the uptake values in prostatic region and metastases were evaluated to define the local recurrence or metastatic disease. Results: In staging group, PSMA PET showed increased uptake in the primary lesion area in 14/27 (52%) patients, whereas 20/27 (74%) patients were positive in FAPI-04 PET. FAPI-04 positivity was found to be quite high, such as 54%, in PSMA-negative patients. A significant difference was observed between ISUP grade 1–3 patients and ISUP grade 4–5 patients in FAPI-04 PET (P = 0.03). Local recurrence was detected in 3 patients, pelvic lymph node metastasis in 1 patient, and sacrum metastasis in 1 patient in biochemical recurrence group, and all of the lesions had more intense uptake in PSMA PET than FAPI-04 PET. Conclusions: FAPI PET imaging seems to have a potential to contribute PSMA PET imaging with FAPI positivity in more than half of PSMA-negative cases. Also, FAPI-targeted radionuclide therapy may be a promising method in patients resistant to PSMA-targeted therapy.Keywords
This publication has 19 references indexed in Scilit:
- Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imagingAnnals of Nuclear Medicine, 2021
- Fibroblast Activation Protein–Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CTClinical Nuclear Medicine, 2021
- High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranosticsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- [68Ga]Ga-DOTA-FAPI-04 PET/CT imaging in a case of prostate cancer with shoulder arthritisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand TherapyEuropean Urology Oncology, 2019
- Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate CancerEuropean Urology, 2019
- 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of CancerJournal of Nuclear Medicine, 2019
- 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate AdenocarcinomaClinical Nuclear Medicine, 2018
- 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various CancersJournal of Nuclear Medicine, 2018